

**Notice of References Cited**

Application/Control No.

09/707,900

Applicant(s)/Patent Under  
Reexamination  
NOH ET AL.

Examiner

Michael Wilson

Art Unit

1633

Page 1 of 2

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-5,842,477	12-1998	Naughton	128/898
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Fox, Biological therapies: A novel approach to the treatment of autoimmune disease, 1995, THE AMERICAN JOURNAL OF MEDICINE, Vol. 99, pp. 82-88
	V	Pelletier et al., In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy, 1997, ARTHRITIS & RHEUMATISM, Vol. 40, pp. 1012-1019
	W	Crystal, Transfer of genes to humans: Early lessons and obstacles to success, 1995, SCIENCE, Vol. 270, pp. 404-410
	X	Deonarain, Ligan-targeted receptor-mediated vectors for gene delivery, 1998, EXP. OPIN. THER. PATENTS, Vol. 8, pp. 53-69

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

<b>Notice of References Cited</b>	Application/Control No. 09/707,900	Applicant(s)/Patent Under Reexamination NOH ET AL.	
	Examiner Michael Wilson	Art Unit 1633	Page 2 of 2

**U.S. PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-			
	B	US-			
	C	US-			
	D	US-			
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

**FOREIGN PATENT DOCUMENTS**

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

**NON-PATENT DOCUMENTS**

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	Miller et al., Targeted vectors for gene therapy, 1995, FASEB J., Vol. 9, pp. 190-199
	V	Van Beuningen et al., Differential effects of local application of BMP-2 or TGF-beta1 on both articular cartilage composition and osteophyte formation, 1998, OSTEOARTHRITIS AND CARTILAGE, Vol. 6, pp. 306-317
	W	Ikeda et al., adenovirus mediated gene delivery to the joints of guinea pigs, 1998, THE JOURNAL OF RHEUMATOLOGY, Vol. 25, pp. 1666-1673
	X	Chernajovsky et al., Pathogenic lymphoid cells engineered to express TGF Beta1 ameliorate disease in a collagen-induced arthritis model, 1997, GENE THERAPY, Vol. 4, pp. 553-559

\*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)  
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.